Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 9/28-10/04.

Q3 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

September 2025 saw 1 new approval, new long term data on smoking and emphysema, and more.

Less than optimal outcomes with ASCVD also increased healthcare resource utilization and costs.

New research supports fimasartan, atorvastatin, and ezetimibe combination to blood pressure and cholesterol levels.

Cytisinicline shows promise as a safe and effective smoking cessation treatment, significantly improving quit rates in COPD.

AstraZeneca's Airsupra gains FDA approval for mild asthma, expanding its current label.

The EXHALE-4 study evaluating the oral small molecule has met its primary endpoint of improving pre-BD FEV1.

Avapritinib shows significant long-term benefits for indolent systemic mastocytosis while maintaining a favorable safety profile.

An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.

Red light photodynamic therapy with 10% ALA gel shows superior clearance rates compared to vehicle treatment.

Baseline emphysema detected in low-dose CT scans predicts long-term mortality in asymptomatic adults.

Regeneron's innovative antibody therapies show promising results in alleviating cat and birch allergies.

Intralesional triamcinolone showed significantly greater hair regrowth and patient satisfaction.

An audio recap of the top 5 stories in healthcare news from the week of 08/31-9/5.

A study links paternal prepubertal passive smoke exposure to impaired lung function in offspring.

August 2025 saw a number of novel approvals and expert perspectives for World Lung Cancer Day.

Agios announces a 3-month extension for mitapivat's FDA review.

The TETON-2 study met its primary endpoint, significantly improveing lung function in IPF.

An audio recap of the top 5 stories in healthcare news from the week of 08/24-08/30.

Finerenone reduced diuretic needs while improving outcomes across various diuretic therapies.

The new guidelines, updated from 2015, are informed by 194 systematic reviews, and 133 RCTs.

The therapy's, marketed as Papzimeos, approval is supported by data from a pivotal Phase 1/2 clinical trial.

Discover how precision medicine and advanced biologics are revolutionizing COPD and asthma management, enhancing patient outcomes and quality of life.

The therapy was approved based off of positive data from the pivotal ASPEN trial.

One year after neffy's approval, 4 clinicians and 1 PharmD examine its continuing impact on the field.

July 2025 saw a number of updates in COPD management and new research on RSV and COVID.

Discover the evolving landscape of hypertriglyceridemia treatment, focusing on innovative therapies and improved diagnostic strategies for FCS and MCS.